Balyasny Asset Management
CLSD

Balyasny Asset Management’s Clearside Biomedical CLSD Stock Holding History

Balyasny Asset Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,496
Closed -$25K – 2826
2022
Q3 		$25K Buy
+1,496
New +$32.8K ﹤0.01% 2553
2022
Q1 		– Sell
-1,251
Closed -$52K – 2515
2021
Q4 		$52K Buy
+1,251
New +$81K ﹤0.01% 2065

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Balyasny Asset Management's CLSD Position: Q4 2022 in Review

Balyasny Asset Management sold out of Clearside Biomedical (CLSD) in Q4 2022, closing a stake of 1,496 shares — an estimated $25K sold.

Balyasny Asset Management first reported a position in CLSD in Q4 2021 and held it in 2 quarters. The position peaked at $52K in Q4 2021. 53 funds tracked by Wall St. Rank hold CLSD as of Q4 2022.

  • Balyasny Asset Management reported no remaining Clearside Biomedical position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 1,496 Clearside Biomedical shares in Q4 2022, an estimated $25K.
  • Balyasny Asset Management first reported a position in Clearside Biomedical in Q4 2021 and held it in 2 quarters.
  • Balyasny Asset Management's Clearside Biomedical position peaked at $52K in Q4 2021.
  • 53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.